FOSCARNET PRESCRIBING INFORMATION PDF

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: Kilabar Vudoll
Country: Andorra
Language: English (Spanish)
Genre: Video
Published (Last): 14 September 2017
Pages: 97
PDF File Size: 9.6 Mb
ePub File Size: 13.51 Mb
ISBN: 750-5-24791-995-4
Downloads: 82288
Price: Free* [*Free Regsitration Required]
Uploader: Zurn

Paroxetine Foscarnet may decrease the excretion rate of Paroxetine which could result in a higher serum level. Memantine Foscarnet may decrease the excretion rate of Memantine which could result in a higher serum level. Equivalent oral rehydration may be considered for certain patients. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as buprenorphine.

Baricitinib Foscarnet may decrease the excretion rate of Baricitinib which could result in a higher serum level. Magnesium Trisilicate Foscarnet may decrease the excretion rate of Magnesium Trisilicate which could result in a higher serum level. Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Foscarnet.

An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as pentamidine. Degarelix The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Degarelix. Foscarnet should be administered by the intravenous route only, either by a central venous line or in a peripheral vein.

  8051 OPCODE SHEET PDF

Foscarnet – DrugBank

Penbutolol Foscarnet may decrease the excretion rate of Penbutolol which could result in a higher serum informahion. Amiodarone The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Amiodarone. Sulfisoxazole The niformation or severity of QTc prolongation can be increased when Foscarnet is combined with Sulfisoxazole. Alimemazine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Alimemazine.

Potassium acetate Foscarnet may decrease the excretion rate of Potassium acetate which could result in a higher serum level.

PDR Search

Foscarnet Injection pronounced as fos kar’ net. Concurrent administration of drugs possessing nephrotoxic effects with Aldesleukin, such as foscarnet, may increase the risk of kidney dysfunction. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as anagrelide.

Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Foscarnet. Rare cases of QT prolongation and TdP have also been reported with ciprofloxacin during postmarketing surveillance.

Both QT prolongation and torsade de pointes TdP have been reported during postmarketing experience with foscarnet.

Arformoterol Foscarnet may decrease the excretion rate of Arformoterol which could result in a higher serum level. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as asenapine.

Loperamide The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Loperamide. Haloperidol The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol. Amifampridine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Amifampridine.

  ATRVETE A AMARME CHRISTIE RIDGWAY PDF

Major Avoid coadministration of ivosidenib with foscarnet due to an increased risk of QT prolongation. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as dasatinib.

Closely monitor renal function and adjust telavancin doses based on calculated creatinine clearance.

Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. Pentastarch Foscarnet may decrease the excretion rate of Pentastarch which could result in a higher serum level. Overdose has been reported during the use of Foscavir, the highest being some 20 times the recommended dose.

Foscavir 24 mg/ml Solution for Infusion

Overdosage Overdose has been reported in 33 patients, the highest dose being about 10 times the prescribed dose. Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine: Cocaine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Cocaine. Cisplatin The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet.

Major Systemic polymyxin B should not be used concurrently or sequentially with other drugs that have the potential for nephrotoxicity or neurotoxicity such as foscarnet. Moxisylyte Foscarnet may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Moderate The risk of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents, including gold compounds.